Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by hoffbagon Mar 16, 2021 4:38pm
111 Views
Post# 32810018

RE:RE:RE:Large volumes

RE:RE:RE:Large volumes Three areas to improve and one additional comment (and I wont send a bill).

1) stop buying more shares - its not working and there is no floor, SOLVE THE PROBLEMS (my prediction is that Knight starts to trade in the 4's very shortly)
2) related to above ...dont file a shelf prospectus to issue shares when you have been buying them for higher prices.  That just tells me that..... (see 3 below) 
3) managment team has to get its act together ..... at the very least give the impression that they have things under control.  Have a plan, have countermeasures for the plan, know some facts and data to respond with.  Include a message you need/want to convey.  The message I am interpreting is that they dont have a plan, they cant sell products because of COVID (disruption to their sales model) and they didnt seem to have any data with which to respond to questions.

I didnt mention it in the previous post, but Jonathan Goodman, the gentleman that everyone is paying to watch, made two comments in the transcript I read.  None substantive and even when the M&A question came up, it was NON-addressed by someone else.
When your team is floundering you have to recognize it and - STEP UP.  
<< Previous
Bullboard Posts
Next >>